TrialThe Lancet. Oncology2025

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

Andre P Fay et al.PubMed ↗Publisher ↗

No numbers read from the abstract.